**Noncalcemic Actions of Vitamin D Receptor Ligands**

Sunil Nagpal, Songqing Na, and Radhakrishnan Rathnachalam

Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285

1α,25-Dihydroxyvitamin D₃ [1,25-(OH)₂D₃], the active metabolite of vitamin D₃, is known for the maintenance of mineral homeostasis and normal skeletal architecture. However, apart from these traditional calcium-related actions, 1,25-(OH)₂D₃ and its synthetic analogs are being increasingly recognized for their potent antiproliferative, prodifferentiative, and immunomodulatory activities. These actions of 1,25-(OH)₂D₃ are mediated through vitamin D receptor (VDR), which belongs to the superfamily of steroid/thyroid hormone nuclear receptors. Physiological and pharmacological actions of 1,25-(OH)₂D₃ ligands in target cells, have indicated potential therapeutic applications of VDR ligands in inflammation (rheumatoid arthritis, psoriatic arthritis), dermatological indications (psoriasis, actinic keratosis, seborrheic dermatitis, photoaging), osteoporosis (postmenopausal and steroid-induced osteoporosis), cancers (prostate, colon, breast, myelodysplasia, leukemia, head and neck squamous cell carcinoma, and basal cell carcinoma), secondary hyperparathyroidism, and autoimmune diseases (systemic lupus erythematosus, type I diabetes, multiple sclerosis, and organ transplantation). As a result, VDR ligands have been developed for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism. Furthermore, encouraging results have been obtained with VDR ligands in clinical trials of prostate cancer and hepatocellular carcinoma. This review deals with the molecular aspects of noncalcemic actions of vitamin D analogs that account for the efficacy of VDR ligands in the above-mentioned indications.

First Published Online March 29, 2005

Abbreviations: AF-1, Activation function-1; AP1, activator protein 1; APC, antigen-presenting cell; BMD, bone mineral density; BPH, benign prostate hyperplasia; CBP, CREB binding protein; CDK, cyclin-dependent kinase; CDK1, CDK inhibitor; CE, cornified envelope; CNS, central nervous system; DC, dendritic cell; DRIP, VDR interacting protein; EAE, experimental allergic encephalomyelitis; EGF-R, epidermal growth factor receptor; ER, estrogen receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IBM, inflammatory bowel disease; IFN, interferon; IGFBP, IGF binding protein; KS, Kaposi’s sarcoma; LBD, ligand binding domain; 2MD, 2-methylene-19 nor-(20S)-1,25-(OH)₂D₃; MDS, myelodysplastic syndromes; MHC, major histocompatibility complex; MMP, matrix metalloproteinase; MS, multiple sclerosis; NcoA, NR coactivator; NF, nuclear factor; NOD, nonobese diabetic; NR, nuclear receptor; 1,25-(OH)₂D₃, 1α,25-Dihydroxyvitamin D₃; PBMC, peripheral blood mononuclear cell; pCAF, p300/CBP-associated factor; PGE₂, prostaglandin E₂; PLC, phospholipase C; PSA, prostate-specific antigen; RA, rheumatoid arthritis; RANKL, receptor activator of NF-kB ligand; RAR, retinoic acid receptor; RXR, retinoid X receptor; SCC, squamous cell carcinoma; SLE, systemic lupus erythematosus; SRE, steroid receptor coactivator; TAF, TATA binding protein-associated factor; TCF, T cell transcription factor; TGase, transglutaminase; Th, T helper; VDR, vitamin D receptor; VDRE, vitamin D₃ response element; ZO, zonula occludens.

Endocrine Reviews is published bimonthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.

---

**I. Introduction**

The biological actions of the hormonally active form of vitamin D₃, 1α,25-dihydroxyvitamin D₃ [1,25-(OH)₂D₃] or calcitriol (Fig. 1), and its synthetic analogs are mediated by the nuclear vitamin D receptor (VDR). VDR is a ligand-dependent transcription factor belonging to the superfamily of steroid/thyroid hormone receptors (1) and has traditionally been associated with calcemic activities, namely, calcium and phosphorus homeostasis and maintenance of bone content. However, the observation that VDR is also present in cells other than those of the intestine, kidney, and parathyroid gland led to the recognition of noncalcemic actions of VDR ligands. As a result, VDR is also known to be involved in cell proliferation, differentiation, and immunomodulation. For example, activated T and B lymphocytes, rheumatoid arthritis (RA) synoviocytes and macrophages, Kaposi’s sarcoma (KS), and prostate, breast, and colon cancer cells exhibit increased levels of VDR protein when compared with their normal counterparts. This activation or disease-specific up-regulation of VDR protein provides an opportunity to treat conditions with VDR...
The expression of VDR in a variety of cell lines and primary cells, coupled with the increased evidence regarding the involvement of VDR in the processes of cell differentiation, inhibition of proliferation, and immunoregulation, has prompted testing of the therapeutic effect of VDR ligands in several human diseases (Table 1) as well as in various animal models of diseases. These efforts have led to the development of VDR ligands for the treatment of psoriasis (2–4), secondary hyperparathyroidism (5), and osteoporosis (6, 7). In addition, VDR ligands have shown some efficacy in limited open clinical trials for prostate cancer, myelodysplasia (a precancerous state), psoriatic arthritis, and RA. Examples of vitamin D analogs that have undergone clinical trials with positive outcome are shown in Table 1. VDR ligands have also shown efficacy in the prevention and treatment of inflammatory and autoimmune diseases in various animal models. The goal of this article is to review the progress in the field of noncalcemic actions of vitamin D and its analogs with a particular emphasis on the current and potential therapeutic applications of VDR ligands. To limit the references to a reasonable number, many recent up-to-date reviews are included, sometimes in place of relevant articles. We apologize to our colleagues when, due to lack of space, a recent review article is mentioned instead of the multiple original references.

II. VDR and the Regulation of Gene Expression

A. VDR and its functional unit

At the molecular level, 1,25-(OH)_{2}D_{3} and its synthetic analogs modulate gene expression through a heterodimer between VDR and retinoid X receptor (RXR). RXR, a nuclear receptor for 9-cis retinoic acid, is an obligate partner of VDR in mediating 1,25-(OH)_{2}D_{3} action (1, 8). In the absence of ligand and serum in cellular systems, most of the VDR is

<table>
<thead>
<tr>
<th>Compound</th>
<th>R</th>
<th>Compound</th>
<th>R</th>
</tr>
</thead>
<tbody>
<tr>
<td>1α,25-(OH)<em>{2}D</em>{3} (Calcitriol)</td>
<td></td>
<td>1α,25-(OH)<em>{2}-22,24-diene-24a,26a,27a-trihomo-D</em>{3} (EB 1099)</td>
<td></td>
</tr>
<tr>
<td>1α,24-(OH)D_{3} (Calcitriol)</td>
<td></td>
<td>1α,25-(OH)<em>{2}22-ene-25-oxa-D</em>{3} (ZK 156718)</td>
<td></td>
</tr>
<tr>
<td>1α,25-(OH)<em>{2}-24-cyclopropyl-D</em>{3} (Calcipotriol)</td>
<td></td>
<td>25-(4-methyliothiazol-2-y)calcipotriol (ZK 191732)</td>
<td></td>
</tr>
<tr>
<td>1α,25-(OH)<em>{2}22-oxa-D</em>{3} (Mixacalcitol)</td>
<td></td>
<td>1α,24R-(OH)<em>{2}D</em>{3} (Tacalcitol)</td>
<td></td>
</tr>
<tr>
<td>1α,25-(OH)<em>{2}D</em>{3} (Calcitriol)</td>
<td></td>
<td>ED-71 (1α,25-(OH)<em>{2}-2-(3-hydroxypropyl)D</em>{3})</td>
<td></td>
</tr>
</tbody>
</table>

Fig. 1. 1,25-(OH)_{2}D_{3} and its synthetic analogs. Structures, common names, and chemical names of vitamin D analogs are presented.
The NH2-terminal region contains a ligand-independent motif that has been described in the promoter region of human CYP3A4 gene (12). The VDR protein is modular in nature and like other nuclear receptors can be functionally divided into three regions with well-characterized functions. The C-terminal region of the receptor contains a multifunctional domain harboring the ligand binding domain (LBD), the RXR heterodimerization motif, and a ligand-dependent transactivation function, AF-2. A VDR ligand binds to the LBD of VDR, and the ensuing conformational change results in the enhancement of VDR-RXR heterodimer formation (10). Unlike other nuclear receptors, AF-1 is not well developed in VDR, and it remains to be seen whether the AF-1 region of the longer version of VDR plays a significant role in VDR-mediated transactivation. The central region contains the DNA binding domain consisting of two C2-C2 type zinc fingers, which target the receptor to VDREs. The C-terminal region of the receptor contains a multifunctional domain harboring the ligand binding domain (LBD), the RXR heterodimerization motif, and a ligand-dependent transactivation function, AF-2. A VDR ligand binds to the LBD of VDR, and the ensuing conformational change results in the enhancement of VDR-RXR heterodimer formation (10). Unlike other nuclear receptors, there is only one isoform encoded by a single gene in humans and other organisms. However, 14 distinct transcripts of VDR have been reported that differ in their 5’ termini and are produced as a result of alternative splicing and differential promoter usage. Most of the variant transcripts produce the same classical VDR protein of 427 amino acids (13).

B. Regulation of gene expression

VDR is a ligand-dependent transcription factor that can modulate the expression of vitamin D-responsive genes in three different ways (Fig. 2). It can positively regulate the expression of certain genes by binding to the VDREs present in their promoter regions (1, 8), or negatively regulate the expression of other genes by binding to negative VDREs (14, 15), or inhibit the expression of some genes by antagonizing the action of certain transcription factors, such as nuclear factor (NF)-κB and NF-κB (16–18). Genes whose expression is induced by VDR ligands, and which are known to contain a VDRE in their promoter, are presented in Fig. 2 along with their known function. These genes include osteocalcin, osteopontin, receptor activator of NF-κB ligand (RANKL), and carbonic anhydrase II, which are involved in extracellular bone matrix formation and bone remodeling (1, 19–24). Other genes that contain a VDRE in their promoter region and show vitamin D-dependent up-regulation in their expression are the cell adhesion molecule β3 integrin, tumor suppressor p21, calcibindin-9k, 24-hydroxylase, human CYP3A4 and its rat and mouse CYP counterparts, involucrin, phospholipase C (PLC) γ1, and IGF binding protein (IGFBP)-3 (1, 12, 25–32). Genes that are down-regulated in response to 1,25-(OH)2D3 and its synthetic analogs are also listed in Fig. 2. The known hyperproliferative and inflammatory functions of these gene products indicate that many of the therapeutic effects of 1,25-(OH)2D3 and its analogs are also mediated in VDR-RXR heterodimer formation (10). Unlike other nuclear receptors, there is only one isoform encoded by a single gene in humans and other organisms. However, 14 distinct transcripts of VDR have been reported that differ in their 5’ termini and are produced as a result of alternative splicing and differential promoter usage. Most of the variant transcripts produce the same classical VDR protein of 427 amino acids (13).

<table>
<thead>
<tr>
<th>VDR ligands</th>
<th>Indication</th>
<th>Outcome</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcitriol</td>
<td>Osteoporosis</td>
<td>BMD increase (4-yr trial)</td>
<td>6</td>
</tr>
<tr>
<td>Calcitriol</td>
<td>Osteoporosis</td>
<td>Reduced rate of vertebral fractures</td>
<td>255</td>
</tr>
<tr>
<td>EB 1089</td>
<td>HCC</td>
<td>2 of 33 Patients complete response</td>
<td>269</td>
</tr>
<tr>
<td>(Seocalcitol)</td>
<td></td>
<td>12 of 33 Stable disease</td>
<td></td>
</tr>
<tr>
<td>Calcitriol (oral)</td>
<td>Psoriasis</td>
<td>Improvement in 88% of patients</td>
<td>270</td>
</tr>
<tr>
<td>Calcitriol (topical)</td>
<td>Psoriasis</td>
<td>Improvement in 79% of patients</td>
<td>155</td>
</tr>
<tr>
<td>Calcipotriol</td>
<td>Psoriasis</td>
<td>Disease improvement</td>
<td>153</td>
</tr>
<tr>
<td>Tacalcitol</td>
<td>Psoriasis</td>
<td>Improvement in PASI score</td>
<td>271</td>
</tr>
<tr>
<td>Maxacalcitol (OCT)</td>
<td>Psoriasis</td>
<td>Improvement in PASI score</td>
<td>272</td>
</tr>
<tr>
<td>ED-71</td>
<td>Osteoporosis</td>
<td>BMD increase (phase II trial)</td>
<td>261</td>
</tr>
<tr>
<td>RS-980400</td>
<td>Osteoporosis</td>
<td>BMD increase (phase II trial)</td>
<td>273</td>
</tr>
<tr>
<td>Faraicalciol</td>
<td>2HPT</td>
<td>PTH suppression</td>
<td>274</td>
</tr>
<tr>
<td>OCT</td>
<td>2HPT</td>
<td>PTH suppression</td>
<td>275</td>
</tr>
<tr>
<td>Alfalcacidol</td>
<td>MDS</td>
<td>Leukemia-free survival</td>
<td>241</td>
</tr>
<tr>
<td>Alfalcacidol</td>
<td>Arthritis</td>
<td>Disease improvement</td>
<td>110</td>
</tr>
<tr>
<td>Calcitriol</td>
<td>PA</td>
<td>Disease improvement</td>
<td>109</td>
</tr>
<tr>
<td>Calcitriol</td>
<td>Prostate cancer</td>
<td>Decrease in PSA rise</td>
<td>186</td>
</tr>
<tr>
<td>Calcitriol</td>
<td>Prostate cancer</td>
<td>Survival and decrease in PSA rise</td>
<td>190</td>
</tr>
<tr>
<td>Calcipotriol</td>
<td>KS</td>
<td>Decrease in tumor size</td>
<td>249</td>
</tr>
</tbody>
</table>

HCC, Hepatocellular carcinoma; 2HPT, secondary hyperparathyroidism; PA, psoriatic arthritis; PASI, psoriasis area and severity index; OCT, 22-oxacalcitrol.
ocytes) (37), c-myc (keratinocytes) (37), and K16 (psoriatic plaques) (38). PTH (parathyroid cells) (39) and PTHrP (osteoblasts and keratinocytes) (40, 41) that are involved in mineral homeostasis are also down-regulated by VDR ligands. Recently, rel B (NF-H9260 element) showed vitamin D-dependent down-regulation in dendritic cells (DCs) (14). Negative regulation of PTH (42), PTHrP (43), and rel B (14) gene expression appears to occur through a DNA motif, called negative VDRE. However, the mechanism of VDR-dependent inhibition of IL-2 and GM-CSF expression appears to be more complex than the involvement of positive or negative VDREs. In the case of these cytokines, VDR first competes with NF-AT1 for binding to the composite NF-AT1-activator protein 1 (AP1) enhancer motif, and then it interacts with c-Jun. This apparent co-occupancy of the composite site by VDR-c-Jun leads to inhibition of activated IL-2 and GM-CSF expression (16, 17, 44). Both VDR monomers and VDR-RXR heterodimers are involved in inhibition of IL-2 and GM-CSF promoters.

C. VDR cofactors

Vitamin D-dependent transcription requires the binding of ligand-occupied RXR-VDR heterodimers to VDREs present in the upstream regions of responsive genes. The ligand binding in general increases the affinity of VDR with various proteins called cofactors that act as a bridge between the RXR-VDR heterodimer and the basal Pol II transcription machinery. Using genetic and biochemical approaches, a number of cofactors that interact with VDR and other nuclear receptors in a ligand-dependent manner have been identified. VDR-interacting cofactors are listed in Table 2. Cofactor proteins do not show any DNA binding activity but possess the capability to modulate gene expression in transfected systems.

Cofactors include two functionally distinct families of proteins, namely coactivators and corepressors. Coactivators mediate induction of transcription, whereas the reciprocal family of corepressors binds to the unliganded or antagonist-occupied nuclear receptors and suppresses the expression of responsive genes. The identification of cofactors provided an increased understanding of the process of transcription, because these proteins provided either the chromatin-modifying enzymatic activities or acted as a platform for the recruitment of histone-destabilizing/stabilizing enzymatic activities or recruited basal transcription factors to the ligand-responsive promoters. The steroid receptor coactivator (SRC) family of cofactors includes three members, namely SRC-1, SRC-2, and SRC-3 (Table 2). SRC family members, along with CBP (CREB binding protein)/p300 and pCAF (p300/CBP-associated factor), are histone acetyltransferases that destabilize the nucleosomal core by catalyzing the acetylation of lysine residues present in the N-terminal tails of histones (45). Thyroid receptor interacting protein 1/Sug1 interacts with the VDR in a ligand-dependent manner and may act as a mediator for transcription or direct the receptor to ligand-dependent proteosomal degradation (46–48). Sug1 has also been found to have DNA helicase activity (49). Therefore, thyroid receptor interacting protein 1/Sug1 may perform various roles by forming different complexes in a cell context-dependent manner (Table 2). SKIP (ski-interacting protein)/nuclear receptor (NR) coactivator (NcoA)-62 synergized with SRC-1 and SRC-2 to induce RXR-VDR-mediated ligand-dependent transactivation. This synergy was explained by the observations that NcoA-62 formed a ternary complex with VDR and SRC-2, wherein NcoA-62 and SRC-2 interacted with VDR through helices H10 and H12, respectively (50, 51). The SRC family members, CBP/p300, NcoA-62, and TATA binding protein-associated factors (TAFs), act
as transcriptional coactivators and strongly potentiate ligand-dependent activation of transcription by VDR and other members of the nuclear receptor superfamily. VDR also directly interacts with certain components of the basal transcription machinery including TF-IIB, TF-IIA, and TAFs, e.g., TAFII135, TAFII55, and TAFII28 (52–54).

A complex of approximately 20 proteins called DRIP (VDR-interacting proteins)/SMCC (SRB- and MED-containing cofactor complex)/TRAP (thyroid hormone receptor-associated protein)/ARC (activator-recruited cofactor) that interacts with VDR, other nuclear receptors, and transcription factors has been described (55). The DRIP complex was found to be sufficient for in vitro ligand-dependent transcription by the RXR-VDR heterodimer (55). The RXR-VDR recruits the complete DRIP complex by ligand-mediated interaction with DRIP 205, a component of the complex. The current working model for the vitamin D-mediated transcription is thought to require ligand-dependent targeted recruitment of VDR-DRIP and VDR-SRC complexes to the VDRE in a sequential manner (56). The first step involves the recruitment of VDR-DRIP and VDR-SRC complexes to the VDRE, followed by the recruitment of SRC-1 (SRC-1/NCoA-1) and SRC-3 (SRC-3/p210CIP/ACTR/AIB1/TRAM-1/NCoA-3). These corepressors recruit histone deacetylase activities that may exist. Understandably, with the discovery of a plethora of receptor-interacting complexes, the transcription picture has become more complicated. But this scenario also provides an opportunity of increased understanding of tissue- and gene-selective transcription by natural and synthetic ligands.

### III. VDR Crystal Structure

Although structures for many nuclear receptors with or without ligands were available, obtaining a good model for 1,25-(OH)$_2$D$_3$ complexed VDR was challenging. The VDR-LBD has an insertion domain from amino acid residues 165–215 that is poorly conserved between different species, with no obvious biological significance (59). Rochel et al. (60) engineered a VDR LBD lacking this loop and characterized this mutant protein to prove that it was able to bind the natural ligand and was also capable of transactivation. This mutant VDR-LBD was crystallized to solve the structure of the ligand-bound receptor. The crystal structure of the LBD of mutant VDR (60) resembles that of other nuclear receptors displaying three layers of 13–α helices and a short β-sheet of three strands (Fig. 3, A and B). The nomenclature of helices is based on the description of the structure of RXRα LBD (61). Members of the nuclear receptor superfAMILY exhibit not
Fig. 3. Topology of VDR LBD crystal structures (x-ray coordinates; Protein Data Bank ID code 1DB1). A. Crystal structure of 1,25-(OH)2D3 bound to LBD of VDR is shown. The helices (H1-H12) are represented as cylinders (red, except helix-12 which is pink), β-sheets are represented as arrows in yellow, and the ligand is shown in white. Positioning of the ligand in the ligand-binding cavity is clearly shown by making helices H3 and H2 translucent. B, Ribbon diagram of the VDR LBD in stereo. The 1,25-(OH)2D3 is represented as ball and stick embedded in translucent surface in pink color. The helices are numbered as H1, H3, H5, H11, and H12. Few of the residues close to the ligand are displayed in stick model identified with one letter amino acid code and the residue number in blue. The helix-7 (H7) is directly behind the ligand in this orientation and thus is not visible. However, its location can be seen in panel A, which is represented as cylinders. These figures were produced using the published crystal structure coordinates (60).
only the same modular domain structure but also a moderately conserved LBD (60). The canonical folds of LBDs of all nuclear receptors consist of 10–13 α-helices, two to five β-sheets arranged in antiparallel orientations, and connecting loops of varying sizes (62). The relative position of N-terminal helix H1 is conserved among all nuclear receptors, and it provides intramolecular contacts for the stabilization of the global structure of LBD. In VDR, helices H1 and H3 are connected by two short helices, H2 and H3n, where H3n is predicted by secondary structure predictions in the place of a loop structure that is present in other nuclear receptors (60). The crystal structure of VDR LBD closely resembles that of retinoic acid receptor (RAR)-γ. However, a very conspicuous difference between VDR and RARγ is that the loop connecting H1 and H3 (shown in green for RARγ in Fig. 4) wraps around the three-stranded short β-sheet in RARγ (63), whereas it just passes by one end of β-sheet in VDR (shown in pink in Fig. 4), thus leaving the sheet exposed. Note that the β-sheets of RARγ are shown in blue, and those of VDR are shown in red (Fig. 4). Concomitantly, the loop connecting the β-strand-2 (β2) and β-strand-3 (β3) in VDR depicted in red is folded out of the 1,25-(OH)2D3-binding pocket, whereas the corresponding loop in RARγ (depicted in blue) is pointing toward the pocket, thus making the pocket smaller in RARγ.

The structure of the liganded VDR LBD (60) gives an opportunity to understand possible interactions between the natural ligand and the receptor. The structure of the receptor-ligand complex revealed that all the β-sheet residues contact the ligand. Trp-286 that is specific to VDR plays the crucial role of positioning the ligand. Trp-286 for VDR is shown in Fig. 4), whereas the 1,25-(OH)2D3-binding pocket, whereas the corresponding loop in RARγ (depicted in blue) is pointing toward the pocket, thus making the pocket smaller in RARγ. The positioning of the helix H12 that is crucial for the coactivator binding and transactivation represents the agonist position in the published structure. This makes two direct Van der Waals contacts (Val-418 and Phe-422) with the methyl groups of the ligand, thus indicating the modulation of helix H12 conformation and positioning by the ligand (60). The position of helix H12 is also stabilized by a number of hydrophobic contacts and polar interactions (Val-234, Ile-268, His-397, and Tyr-401). The helix H12 residue Glu-420 that makes a salt bridge with Lys-264 of helix H4 has been implicated in ligand-dependent transactivation (64). Recently, computer docking of a VDR ligand specific for the nongenomic actions has resulted in the identification of an alternative ligand binding pocket (A-pocket) that partially overlaps the 1,25-(OH)2D3-binding pocket (G-pocket) identified in the VDR-LBD crystal structure (65). Although modeling studies showed this alternative ligand-binding pocket in the VDR, the crystal structure of estrogen receptor β (ERβ) associated with 4-hydroxytamoxifen revealed two molecules of 4-hydroxytamoxifen bound to the protein (66). The ERβ second ligand-binding pocket resembles the A-pocket of VDR and might be a unifying feature of the nuclear receptor superfamily. The elucidation of the crystal structure provides an opportunity for medicinal chemists to design and synthesize novel, nonsteroidal, high-affinity VDR ligands for the treatment of responsive indications.
IV. VDR Knockout Animals

Gene knockout studies in mice and VDR mutations in humans have provided considerable insights into the physiological functions of vitamin D. Four groups have created VDR knockout animals (67–71). VDR null mice were phenotypically normal at birth but developed hypocalcemia, hyperparathyroidism, rickets/osteomalacia, and alopecia after weaning. Female null mutant mice also displayed uterine hypoplasia and impaired folliculogenesis. These mice died between 4 and 6 months of age. Similar symptoms occur in kindreds with VDR mutations in vitamin D-dependent rickets type II. Interestingly, feeding animals with a diet rich in calcium, phosphate, and lactose normalized all the symptoms in null mice, except for hair abnormalities. These observations suggest that increased intestinal calcium absorption is critical for 1,25-(OH)2D3 action on bone and calcium homeostasis. The calcium homeostasis defect could be explained by the reduced expression of duodenal epithelial calcium channels CAT1 and CAT2 in VDR null mice (71).

Vitamin D-deficient animals have also been shown to develop hypocalcemia, rickets, and hyperparathyroidism, but unlike vitamin D-dependent rickets type II patients, never developed alopecia. Thus, intact VDR is required for maintaining bone mineral homeostasis after birth as well as for normal hair development and hair follicle homeostasis. Hair-reconstitution studies in nude mice using VDR−/− keratinocytes showed normal hair follicle morphogenesis but a defective response to anagen initiation phase of the hair cycle (72). These studies also indicated that the defect lies in keratinocytes. In accordance with this notion, targeted expression of human VDR transgene to keratinocytes of VDR null mice prevented alopecia (73). Therefore, hair loss in VDR−/− mice appears to be due to keratinocytes defective in epithelial-mesenchymal interactions that are required for normal hair cycling.

Similar hair cycle defect with total alopecia was also observed in inactivating mutation in hairless (hr) gene and in mice with temporally controlled RXRα mutations in the epidermis. Hairless gene product (Hr) acts as a corepressor of VDR, thyroid hormone receptor, and RAR-related orphan receptor α, and associates with VDR in vitro and in vivo (74). It is tempting to hypothesize that VDR-Hr interaction may modulate hair cycling by controlling the expression of an inhibitor of hair cycle. Epidermis-specific temporal disruption of RXRα in mouse showed alopecia and skin abnormalities (75). Like VDR ablation, progressive alopecia in epidermal targeted RXRα−/− animals was attributed to defects in hair cycle. Because RXR is the heterodimer partner of other nuclear receptors (RAR, peroxisome proliferator activated...
receptor, liver X receptor, and thyroid hormone receptor) resident in skin, these results suggest that only the RXR-VDR signaling pathway is involved in hair cycling. Furthermore, the absence of keratinocyte differentiation abnormalities in the VDR null animals (76), but the presence of these defects in the temporally controlled RXRα mutation in mouse epidermis points toward the redundancy of RXR partner nuclear receptor functions in mouse skin. VDR knockout mice were also found to have impaired insulin secretory capacity (77).

VDR/RXRα compound null mutant mice have also been prepared and showed growth retardation, impaired bone formation, hypocalcemia, and alopecia, features typical of VDR null animals (78). The growth plate development in compound knockout animals was more severely impaired in comparison to VDR null animals. These findings indicate that both vitamin A and vitamin D signaling pathways are required for the normal development of growth plate chondrocytes.

V. Vitamin D Action in Autoimmune Disease Models

In addition to its central role in calcium and bone metabolism, 1,25-(OH)_2D_3 has potent immunomodulatory effects on many immune cell types, including both innate and adaptive immune cells (79–81). Consistent with these effects, the VDR is widely expressed in most immune cell types such as antigen-presenting cells (APCs; monocyte/macrophage, DCs), natural killer cells (82, 83), T cells (84), and B cells (85). Furthermore, the intriguing effects of 1,25-(OH)_2D_3 have been demonstrated in several autoimmune disease models, namely, systemic lupus erythematosus (SLE) in lpr/lpr mice (86, 87), type I diabetes in nonobese diabetic (NOD) mice (88–92), collagen-induced lupus erythematosus (SLE) in lpr/lpr mice (86, 87), type I diabetes in nonobese diabetic (NOD) mice (88–92), collagen-induced arthritis (93–95), experimental allergic encephalomyelitis (EAE) (96–101), and inflammatory bowel disease (IBD) (102).

A. Multiple sclerosis (MS)

MS is a chronic inflammatory autoimmune disease of the central nervous system (CNS) in which self-epitopes on myelinated nerve fibers are inappropriately recognized by adaptive immune cells of the host. The ensuing immune response recruits T cells and macrophages into the CNS, resulting in localized areas of inflammation and demyelination known as MS lesions. EAE is widely used as an animal model for human MS disease. Self-antigen reactive T helper I (Th1) cells have been demonstrated to play an essential role in both induction and effective phase of disease. Th1 cell differentiation is controlled by both antigen stimulation and cytokines, particularly IL-12 and IL-23, which subsequently induce synthesis of Th1-specific transcription factor, T-bet, and drives Th0 cells toward Th1 differentiation (103). Therefore, controlling Th1 development by inhibiting IL-12 production will benefit the Th1-mediated disease, such as MS. VDR ligands have been shown to inhibit IL-12 p70 production in freshly isolated human monocyte or PBMCs that are primed with IFN-γ and stimulated with lipopolysaccharide in a dose-dependent manner (104). Furthermore, mitogen-induced differentiation of neonatal CD4+ T cells into Th1 cells (IFN-γ secreting T cells) in vitro is dramatically inhibited by 1,25-(OH)_2D_3 and its analogs. Interestingly, the inhibition of Th1 development seems to be specific, because Th2 (IL-4 secreting T cells) cell differentiation is largely unaffected by this treatment (104).

When mice were immunized with self-antigen peptide, myelin oligodendrocyte glycoprotein (MOG35–55), and treated with 1,25-(OH)_2D_3, disease induction was inhibited as evidenced by the reduction of inflammatory infiltration and reduced demyelination of brain and spinal cord, along with decreased antigen-induced T cell proliferation during an in vitro T cell recall response. More importantly, it also inhibited Th1 development (104), suggesting that inhibiting CD4 Th1 effector function is one of the mechanisms by which 1,25-(OH)_2D_3 inhibits EAE. In contrast to CD4+ T cells, the protection of EAE from 1,25-(OH)_2D_3 treatment does not involve CD8+ T cells (97), although CD8+ T cells have the highest levels of VDR and have been implicated as both suppressors and effectors of the inflammation associated with EAE. In addition to effects on T cells, 1,25-(OH)_2D_3 has also been shown to decrease macrophage accumulation in the CNS, which can contribute to its protective effect during EAE (99). When EAE was induced in B10.PL mice after immunization with myelin basic protein, administration of 1,25-(OH)_2D_3 not only prevented the induction of the disease, but also ameliorated the disease when the treatment was administered at the appearance of the first disability symptoms. Interestingly, withdrawal of 1,25-(OH)_2D_3 resulted in the resumption of EAE. Deficiency of vitamin D in the food led to the increased EAE susceptibility in mice, suggesting that daily vitamin D in vivo prevents the occurrence of the autoimmune disease (105). Furthermore, immunization of VDR-deficient mice led to EAE, which was not suppressed by administration of 1,25-(OH)_2D_3, whereas EAE in wild-type animals was completely blocked by this treatment, suggesting that the VDR is necessary and directly involved in 1,25-(OH)_2D_3-mediated suppression of EAE.

Although the mechanism of EAE inhibition by 1,25-(OH)_2D_3 is not completely understood, many studies have clearly implicated that a major effect of VDR ligands is on T cell functions, mainly through inhibiting Th1 cell development and function while enhancing Th2 cell development (106). Administration of 1,25-(OH)_2D_3 in mice increases expression of IL-4 and TGF-β1, which presumably play an important role in regulating T cell responses (100). Accordingly, VDR ligands were found to be less effective in reducing the progression of EAE in IL-4 null mice (102).

B. Rheumatoid arthritis (RA)

RA, one of the most common chronic inflammatory diseases, affects about 1% of the population and is characterized by articular infiltration of neutrophils, macrophages, T and B cells, and DCs, resulting in subsequent tissue damage (107). The collagen-induced arthritis model is the most commonly used arthritis model for human RA. Immunization of mice with type II collagen induces arthritis, which could be prevented by dietary supplementation or oral administration of 1,25-(OH)_2D_3 in both mouse and rat (93–95). More interestingly, administration of 1,25-(OH)_2D_3 or its analogs at the
time of disease with early symptoms could prevent the progression to severe arthritis (92, 94). In addition, treated animals showed diminished serum levels of antibodies to rat collagen type II and reduced mitogen-induced proliferation of lymph node cells (94), suggesting that 1,25-(OH)\textsubscript{2}D\textsubscript{3} suppresses RA by altering adaptive immunity.

Epidemiological studies have reported low serum levels of vitamin D and its metabolites in RA patients (108). In addition, an open-label clinical trial involving patients (Table 1) with psoriatic arthritis showed an improvement in disease symptoms after the oral administration of 1,25-(OH)\textsubscript{2}D\textsubscript{3} (109). More significantly, in a 3-month open-label clinical trial in 19 RA patients being treated with standard disease-modifying antirheumatic drugs therapy for acute RA (Table 1), high-dose oral alfalcacitol (α hydroxyvitamin D\textsubscript{3}; Fig. 1) therapy showed a positive effect on disease activity in 89% of the patients, and only 11% of patients showed no improvement (110). This result provides strong evidence that VDR ligand can be used clinically for the treatment of RA.

1,25-(OH)\textsubscript{2}D\textsubscript{3} has been detected in synovial fluid of arthritic joints, and the expression of VDR has also been reported in rheumatoid synovial tissue and at the site of cartilage erosion. Matrix metalloproteinases (MMPs) play an important role in the chondrolytic process of rheumatoid lesion. Animal studies have shown that the production of some MMPs may be up-regulated in rat chondrocytes by administration of 1,25-(OH)\textsubscript{2}D\textsubscript{3} (111). Interestingly, treatment of rheumatoid synovial fibroblasts by 1,25-(OH)\textsubscript{2}D\textsubscript{3} did not affect the expression of MMPs. However, when simultaneously stimulated with IL-1β, the MMP production was reduced 50% compared with IL-1β alone. Prostaglandins have a role in the immune system and inflammatory processes associated with RA. Interestingly, IL-1β-stimulated prostaglandin E2 (PGE2) synthesis is also completely inhibited by 1,25-(OH)\textsubscript{2}D\textsubscript{3} treatment (112). Therefore, VDR ligand can suppress both the IL-1β-stimulated production of MMP and PGE2 in rheumatoid synovial fibroblasts, suggesting that VDR-mediated biological processes are important in controlling RA. However, the molecular mechanism by which VDR ligands inhibit IL-1β-stimulated MMP and PGE2 production is not known.

C. Inflammatory bowel diseases (IBDs)

IBDs (ulcerative colitis and Crohn’s disease) are immune-mediated pathologies with unknown etiology that target the gastrointestinal tract. T cells, particularly CD4+ Th1 cells, which preferentially produce inflammatory cytokines (IL-2, TNF-α, IFN-γ), have been shown to transfer Crohn’s-like symptoms to naive mice, and the production of Th1 cytokines is associated with IBD in humans (113, 114). Interestingly, IL-10-deficient mice develop colitis within 5–8 wk of life, and one third of these mice die after the development of severe anemia and weight loss (115). In this model, lack of vitamin D in the diet led IL-10 knockout mice to rapidly develop diarrhea, wasting disease, and mortality. In contrast, supplementation with 1,25-(OH)\textsubscript{2}D\textsubscript{3} in diet significantly ameliorated the symptoms of IBD in IL-10 null mice. Similarly, treatment of animals with 1,25-(OH)\textsubscript{2}D\textsubscript{3} blocked the progression and decreased the established IBD symptoms (115). 1,25-(OH)\textsubscript{2}D\textsubscript{3} also inhibited the proliferation of rectal epithelial cells (116) and T cells (117) in active ulcerative colitis patients, suggesting the potential of VDR ligands in the treatment of IBDs.

D. Type I diabetes

Type I diabetes is an autoimmune disease characterized by the immune-mediated destruction of insulin-producing β-cells of islets of Langerhans in the pancreas. Several cellular effector mechanisms leading to β-cell destruction have been identified, including CD4+ and CD8+ T cells and macrophages (118). The NOD mouse, which spontaneously develops type I diabetes, is the most widely used animal model for type I diabetes (119). Based on the effect of VDR ligands on T cell and macrophage functions described earlier, it is reasonable to predict that type I diabetes would be modulated by VDR ligand. Epidemiological studies have shown an increase in the disease incidence when vitamin D deficiency was present in the first month of life in children. Moreover, in a recent study in NOD mice, vitamin D deficiency accelerated the onset of type I diabetes (120).

In fact, when 1,25-(OH)\textsubscript{2}D\textsubscript{3} was administrated at 3 wk of age before the onset of insulitis, it effectively prevented the progression of diabetes in NOD mice. However, treatment was ineffective if administrated at 8 wk of age when insulitis was well established (121). In addition to the natural ligand, a vitamin D analog, KF 1060 (Fig. 1), has also been shown to prevent the onset of type I diabetes in NOD mice (91). Vitamin D analogs were also effective in the treatment of ongoing type I diabetes in the adult NOD mice by effectively blocking the disease course (92), raising the possibility of treatment of type I diabetes with VDR ligands before β-cells are completely destroyed. Treatment of mice with a synthetic 1,25-(OH)\textsubscript{2}D\textsubscript{3} analog also inhibited IL-12 production and blocked the infiltration of Th1 cells into the pancreas. It should be noted that IL-12 is a direct target of 1,25-(OH)\textsubscript{2}D\textsubscript{3} (35). More interestingly, CD4+CD25+ Treg cells were increased by this treatment in pancreatic lymph node (92). In fact, adaptive transfer of pancreatic lymph node-derived Treg cells into NOD mice completely prevented spontaneous diabetes. Interestingly, Treg cells accumulated preferentially in the pancreatic lymph nodes and islets, but not other lymph nodes or the spleen (92). In addition, 1,25-(OH)\textsubscript{2}D\textsubscript{3} could induce an autoantigen-specific Th1 to Th2 immune shift in NOD mice immunized with glutamic acid decarboxylase 65 (89), suggesting that VDR ligands might work on multiple levels to modulate the immune system and prevent autoimmune diseases.

E. Systemic lupus erythematosus (SLE)

SLE is a systemic autoimmune disease. Patients with SLE produce autoantibodies to many tissue antigens including DNA, histones, red blood cells, platelets, and leukocytes, and as a result these individuals present with varying symptoms. The therapeutic potential of VDR ligands for the treatment of SLE was explored using an analog of 1,25-(OH)\textsubscript{2}D\textsubscript{3}, 22-oxa-1α, 25-dihydroxyvitamin D\textsubscript{3} (Fig. 1). Symptoms of SLE were alleviated in MRL/lpr mice after treatment with 22-
calcium homeostasis, vitamin D₃ has been demonstrated to inhibit bone loss.

and/or corticosteroid dosage, which could potentially contribute to hypercalcemia was not observed in the autoimmune animals (122).

F. Transplant rejection

Organ and tissue transplantation are increasingly being performed worldwide, and these procedures many times lead to long-term survival. The commonly used strategy for preventing transplantation rejection involves the use of immunosuppressive agents such as corticosteroids and cyclosporin. 1,25-(OH)₂D₃ exerts a variety of immunomodulatory effects such as inhibition of T lymphocyte proliferation (123–125), down-regulation of cytokines IL-2 and IFN-γ (124), and DC maturation and survival (126). Based on these observations, 1,25-(OH)₂D₃ and its analogs have been tested either as single agents or in combination with other immunosuppressive agents such as cyclosporin in many experimental models, including heart (127, 128), liver (129), pancreatic islets (130, 131), and skin (132, 133). Interestingly, 1,25-(OH)₂D₃ treatment was shown to prolong allograft survival. For example, transplantation of rat islets under the kidney capsule in spontaneously diabetic NOD mice resulted in early graft failure in four of 10 recipients (131). Single treatment of NOD mice with KH1060 (Fig. 1), a vitamin D₃ analog, or cyclosporin did not result in statistically significant suppression of early graft failure. However, combination of both resulted in 100% early graft success (131). Similar results were also reported in chronic allograft rejection, where adventitial inflammation and internal hyperplasia in rat aortic allograft were inhibited by treatment with the VDR ligand (134). In addition to its direct immunosuppressive function in transplantation, 1,25-(OH)₂D₃ and its analogs also demonstrated important impact on the prevention of bone loss and improvement on bone quality after organ transplantation (135–137). The mechanism of vitamin D₃ in preventing transplant osteoporosis is probably due to its effect on hyperparathyroidism caused by the usage of corticosteroids or cyclosporin. Moreover, the immunomodulatory properties of 1,25-(OH)₂D₃ may enable the reduction of cyclosporin and/or corticosteroid dosage, which could potentially contribute to an improvement in posttransplantation-related bone loss.

In addition to its primary physiological role in regulating calcium homeostasis, vitamin D₃ has been demonstrated to have pleiotropic actions in the immune system. 1,25-(OH)₂D₃ was found to inhibit antigen-induced T cell proliferation (138) and cytokine production (139). APCs, in particular DCs, are also the primary targets for the immunosuppressive activity of 1,25-(OH)₂D₃. They play a central role in regulating immune response to self and foreign antigens. During the normal immune response, T cell response and specificity are conferred through the clonal restricted T cell receptor, which recognizes major histocompatibility complex (MHC) class I and class II molecule complexed with peptides. However, the potency of DC-mediated T cell activation also depends on their maturation status. Immature DCs express low levels of MHC class II costimulatory specific maturation markers, such as CD83, whereas mature DCs express high levels of these molecules in response to appropriate proinflammatory stimuli (140, 141). Immature DCs not only provide weak signals for activating T cells but also induce anergic and regulatory T cells (142). Mature DCs have considerably less antigen uptake and demonstrate increased antigen presentation and induction of costimulatory ligands on the surface. These cells also show enhanced production and secretion of immunomodulatory cytokines such as IL-12 (143). The maturation of DCs is regulated by many factors and cell-cell interactions. Among the factors that induce DC maturation are the components of pathological pattern recognition, which are recognized by cell surface Toll-like receptors and many cytokines including TNF-α. T cells can induce DC maturation through their intimate interactions by activating TNF receptor family members expressed on DCs such as CD40. However, it is unknown whether the preservation of DCs in an immature state results from the absence of maturation stimuli or is also actively maintained in vivo.

VDR is widely expressed in most cell types in the immune system such as APCs, monocyte/macrophage, natural killer cells, and DCs (82, 83). 1,25-(OH)₂D₃ could affect DC function through differentiation, cytokine production, activation, maturation, as well as survival (126, 144). The most direct evidence of 1,25-(OH)₂D₃ effect on DCs comes from VDR knockout mouse studies, where DCs from VDR-deficient mice showed a significantly higher level of maturation markers such as class II MHC, CD40, CD80, and CD86 on cell surface (144). Under differentiation conditions in the presence of GM-CSF and IL-4 from purified human CD14+ monocytes, 1,25-(OH)₂D₃ completely inhibited DC differentiation with low-level expression of IL-12 and maturation markers (144, 145). Consequently, 1,25-(OH)₂D₃-treated DCs lead to impaired alloreactive T cell activation in vitro and in vivo (144, 146). Furthermore, 1,25-(OH)₂D₃ also affects maturing DCs, leading to decreased IL-12 secretion and enhanced IL-10 production, which subsequently affects T cell differentiation (126). Recent evidence also pointed out that 1,25-(OH)₂D₃ not only exhibits immunosuppressive effects on T cells and APCs, but also leads to the induction of tolerogenic DCs, which subsequently enhance CD4⁺CD25⁺ regulatory T cells and protect the allograft rejection (147). In conclusion, all the preclinical studies suggest that 1,25-(OH)₂D₃ and its analogs can be potentially used for the prevention of transplant rejection.

In summary, VDR ligands have pleiotropic effects on the immune system, including both innate and adaptive immunity. In particular, their effect on DCs is thought to induce tolerogenic DCs resulting in T cell anergy. Their effect on T cells can lead to the formation of regulatory T cells as well as accelerate Th2 cell development. All of this evidence suggests that VDR ligands have great potential for the development of therapies for multiple human autoimmune diseases. The challenge for the future is to develop safer oral VDR ligands without the hypercalcemic side effect.

VI. Vitamin D Action on Keratinocytes and Psoriasis

Psoriasis, a recurrent inflammatory skin disorder, affects approximately 2% of the population. In addition, 5–10% of
the patients develop psoriatic arthritis, with inflammation and swelling in the hands, feet, and large joints. Psoriasis is characterized by keratinocyte hyperproliferation, abnormal keratinocyte differentiation, and immune-cell infiltration into the epidermis and dermis. The most common form of psoriasis is plaque psoriasis or psoriasis vulgaris. At the molecular level, psoriasis lesions show a prominent loss of loricrin and filaggrin in the suprabasal layers of the epidermis and abnormal overexpression of other differentiation markers such as involucrin, transglutaminase I (TGase I), psoriasin, migration inhibitory factor related protein-8, and skin-derived antileukoproteinase. The expression of normal suprabasal keratins K1 and K10 is inhibited and replaced by the expression of the hyperproliferative keratins K6 and K16. Psoriatic epidermis also demonstrates an increased expression of IL-8 receptor, IL-6, IL-8, EGF-R, TGFAα, and amphiregulin. Lesions also show infiltration of IL-2, IFN-γ, and TNF-α-secreting CD8+ lymphocytes into epidermis and CD4+ lymphocytes into dermis, and these cytokines are thought to alter keratinocyte differentiation and proliferation.

The observations that keratinocytes and T cells express VDR and that 1,25-(OH)2D3 is a potent stimulator of keratinocyte differentiation provided a reasonable basis for the clinical use of VDR ligands for the treatment of psoriasis (82, 148). The first clinical evidence to support the use of vitamin D analogs was obtained fortuitously when a patient treated orally with 1α-hydroxyvitamin D3 (Fig. 1) for osteoporosis showed remarkable remission of psoriatic lesions (149). Subsequently, promising clinical results were obtained in studies using oral 1α-hydroxyvitamin D3 oral and topical 1,25-(OH)2D3 (calcitriol), and topical 1,24-(OH)2D3 (tacalcitol; Fig. 1). In these clinical trials, approximately 70–80% of the patients showed marked improvement, and complete clearance of the target lesions was observed in 20–25% of patients (150). A topical preparation of calcitriol (Silis, 3 μg/g ointment) is being developed by Galderma Laboratories (Sophia-Antipolis, France) for the treatment of psoriasis. It has shown safety and efficacy at a calcitriol concentration of 3 μg/g ointment but resulted in increased risk of hypercalcuria at 15 μg/g concentration (151, 152). Therefore, it appears to show a therapeutic window of 5 between efficacy and side effect. Medicinal chemists have tried to develop 1,25-(OH)2D3 analogs with decreased hypercalcemia liability mostly by minor modifications of the secosteroidal backbone of vitamin D3. Calcipotriol (calcipotriene or Dovonex, Leo Laboratories, Denmark; Fig. 1), a synthetic 1,25-(OH)2D3 analog used topically for the treatment of psoriasis, was chemically engineered to be metabolized quickly in systemic circulation, and as a result it is 100–200 times less calcemic than 1,25-(OH)2D3 (4). A comparison of hypercalcemic properties of calcitriol and calcipotriol is given in Table 3. A number of studies have confirmed the clinical efficacy of calcipotriol, and significant improvement has been observed in approximately 70% of the patients after 6–8 wk of topical therapy with twice daily application of the drug (4). The most common side effect of calcipotriol was cutaneous irritant reaction in approximately 20% of the patients (153). In comparative clinical trials, the efficacy of topical calcitriol was generally similar, and that of topical calcipotriol was slightly better than potent topical steroids (154, 155). Steroids result in early onset of action in psoriasis but cannot be used for longer periods, because of their skin thinning (telangiectasia) side effect, which results because of the alteration in skin collagen metabolism [decrease in type I and type III collagen, TIMP (tissue inhibitor of metalloproteinase) 1 and TIMP 2 message levels] by this class of drugs (156). Therefore, a combination of topical calcitriol or calcipotriol with potent topical steroids has been tried in patients. These clinical studies indicated more rapid onset of action, increased efficacy, and better tolerability of the combination regimens than the individual treatments (157, 158). As a result, a new formulation containing calcipotriol and betamethasone dipropionate (Daivobet, Leo Pharma AS, Ballerup, Denmark) is under consideration by drug regulatory authorities for the treatment of mild-to-moderate plaque-type psoriasis (159).

The antipsoriatic activity of VDR ligands could be attributed to their differentiation, antiproliferative, and immunomodulatory properties. VDR ligands exhibit multipronged effects in psoriatic lesions and affect the function of keratinocytes, T cells, and APCs. VDR ligands promoted differentiation and inhibited the proliferation of keratinocytes (150, 160). Differentiation of keratinocytes results in the formation of a cornified envelope (CE) that provides the barrier function of the skin. The expression of involucrin, a component of the CE, and TGase I, the enzyme that cross-links the components of CE, was increased by 1,25-(OH)2D3 and other

### Table 3. Hypercalcemic activity of VDR ligands

<table>
<thead>
<tr>
<th>Compound</th>
<th>Hypercalcemic dose</th>
<th>Model</th>
<th>Dosing period</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcitriol</td>
<td>15 μg/kg/d</td>
<td>BALB/c mice</td>
<td>3 d</td>
<td>283</td>
</tr>
<tr>
<td>Calcitriol</td>
<td>5 μg/kg/d</td>
<td>BALB/c mice</td>
<td>5 d</td>
<td>283</td>
</tr>
<tr>
<td>Calcitriol</td>
<td>0.2 μg/kg/d</td>
<td>OVX rats</td>
<td>3 wk</td>
<td>262</td>
</tr>
<tr>
<td>ED-71</td>
<td>0.05 μg/kg twice a week</td>
<td>Rats</td>
<td>12 wk</td>
<td>259</td>
</tr>
<tr>
<td>ED-71</td>
<td>0.2 μg/kg twice a week</td>
<td>OVX rats</td>
<td>3 months</td>
<td>258</td>
</tr>
<tr>
<td>2MD</td>
<td>≥1333 pmol/kg 3 times a week</td>
<td>OVX rats</td>
<td>23 wk</td>
<td>264</td>
</tr>
<tr>
<td>Calcitriol</td>
<td>18.7 pmol/kg 7 times a week</td>
<td>OVX rats</td>
<td>23 wk</td>
<td>264</td>
</tr>
<tr>
<td>Calcitriol</td>
<td>&lt;0.5 μg/kg 3 times a week</td>
<td>Copenhagen rats</td>
<td>26 d</td>
<td>175</td>
</tr>
<tr>
<td>EB 1089</td>
<td>&lt;0.5 μg/kg 3 times a week</td>
<td>Copenhagen rats</td>
<td>26 d</td>
<td>175</td>
</tr>
<tr>
<td>Ro-26-6228</td>
<td>&gt;14 μg/kg/d</td>
<td>OVX rats</td>
<td>3 wk</td>
<td>262</td>
</tr>
<tr>
<td>Calcitriol</td>
<td>1 μg/kg/d</td>
<td>Rats</td>
<td>28 d (topical)</td>
<td>284</td>
</tr>
<tr>
<td>Tacalcitol</td>
<td>1 μg/kg/d</td>
<td>Rats</td>
<td>28 d (topical)</td>
<td>284</td>
</tr>
<tr>
<td>Calcipotriol</td>
<td>15 μg/kg/d</td>
<td>Rats</td>
<td>28 d (topical)</td>
<td>284</td>
</tr>
<tr>
<td>BXL-628</td>
<td>300 μg/kg/d</td>
<td>Rats</td>
<td>2 wk</td>
<td>194</td>
</tr>
</tbody>
</table>

OVX, Ovariectomized.
VDR ligands under certain conditions (161). Treatment of keratinocytes with the medium containing high calcium also stimulated keratinocyte differentiation by increasing the expression of involucrin and TGap I. 1,25-(OH)2D3 also promoted keratinocyte differentiation, at least in part by increasing intracellular calcium by two separate mechanisms. 1,25-(OH)2D3 increased the expression of calcium receptor and PLC-γ1 in keratinocytes (162). 1,25-(OH)2D3 may also induce the expression of AP1 transcription factors by the induction of PLC-γ1 (via second messenger inositol phosphate 3) and by inducing the expression of c-Fos (30) (J. Lu and S. Nagpal, unpublished observations). 1,25-(OH)2D3-mediated elevation of AP1 activity may in turn induce the expression of keratin 1, involucrin, TGap I, loricrin, and filaggrin, which are required for CE formation. Genes that are positively and negatively regulated by the treatment of keratinocytes by 1,25-(OH)2D3 are shown (Fig. 6). Expression of EGF-R, c-myc, and keratin 16 was down-regulated in keratinocytes and/or psoriatic lesions after VDR ligand treatment (1).

VDR ligands decreased the expression/level of proinflammatory cytokines IL-2, IFN-γ, IL-6, IL-8, and GM-CSF (1, 33, 34, 36) in T cells, all of which play a role in cutaneous inflammation, and proliferation of T lymphocytes and keratinocytes. Furthermore, topical calcipotriol increased antiinflammatory cytokines IL-10 and decreased IL-8 in psoriatic lesions (163), and 1,25-(OH)2D3 also increased the expression of IL-10 receptor in keratinocytes (164). As a matter of fact, oral less calcemic VDR ligands, which exhibit a multi-pronged effect on all the major cell types involved in psoriasis, have the potential to replace more expensive biological therapies (TNF-α antibodies, soluble TNF-α receptor, etc.), particularly in the face of recent observations that these therapies lose their effectiveness over time in a manner analogous to that of steroids.

APCs or DCs also play an important role in psoriasis and autoimmune diseases because they are involved in autoan-
tigen presentation. It appears that APCs are one of the major targets of 1,25-(OH)2D3-mediated immunosuppressive action and VDR ligands prevent the differentiation, maturation, activation, and survival of DCs, leading to T cell hyporesponsiveness (126). 1,25-(OH)2D3 also increased the expression of IL-10 and decreased the expression of IL-12, two major cytokines that are involved in Th1-Th2 balance (147). It is believed that the development of more efficacious topical and oral VDR ligands, with improved side effect profiles, will further expand the treatment options for patients with psoriasis.

VII. Vitamin D Action on Prostate Cancer Cells

Prostate cancer is the second leading malignancy after skin cancer, and it is also the second leading cause of cancer deaths among men in the United States (165). The discovery that the VDR is expressed in normal prostate, benign prostate hyperplasia (BPH), malignant prostate, and prostate cancer cell lines led to the recognition that BPH and prostate cancer could be potential targets for VDR ligands (166–168). Epidemiological studies have indicated an inverse relationship between mortality rates due to prostate cancer and UV light exposure. UV light is required for the synthesis of vitamin D in skin (169). In fact, one of the major risk factors for developing prostate cancer was low serum level of 25-hydroxyvitamin D (170). Several in vitro studies have demonstrated that 1,25-(OH)2D3 and its synthetic analogs inhibited the proliferation of prostate cancer cell lines (171) and primary epithelial cells from normal prostate, BPH, and prostate cancer (172, 173). VDR ligands also inhibited tumor cell growth and metastasis in vitro (174–177). VDR ligands demonstrate pleiotropic action on prostate cancer cells that include growth arrest at the G0/G1 stage of the cell cycle, apoptosis, tumor cell differentiation, and interaction with androgen signaling pathway. The growth inhibition of cancer cells by VDR li-

<table>
<thead>
<tr>
<th>Prostate</th>
<th>Colon</th>
<th>Breast</th>
<th>Keratino./SCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>p21</td>
<td>p21</td>
<td>p21</td>
<td>TGap I</td>
</tr>
<tr>
<td>p37</td>
<td>p37</td>
<td>p37</td>
<td>Involucrin</td>
</tr>
<tr>
<td>IGFBP-3</td>
<td>E-cadherin</td>
<td>TGF-β1</td>
<td>24-OHase</td>
</tr>
<tr>
<td>IGFBP-5</td>
<td>ZO-1</td>
<td>HOx4B</td>
<td>IL-10R</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>ZO-2</td>
<td>IGFBP-3</td>
<td>PCL-01</td>
</tr>
<tr>
<td>DUSP-10</td>
<td>CAT1</td>
<td>PCL-24</td>
<td>TGF-β1</td>
</tr>
<tr>
<td>TRK1</td>
<td>CAT2</td>
<td>c-Fos</td>
<td>Calcium receptor</td>
</tr>
<tr>
<td>SOD2</td>
<td>c-Jun</td>
<td>JunB</td>
<td>e-Fos</td>
</tr>
<tr>
<td>24-OHase</td>
<td>JunD</td>
<td>FREAC-1/Fox1</td>
<td>VDUP1</td>
</tr>
<tr>
<td>Metallo-</td>
<td>FRA1C/Fox1</td>
<td>ZNF440X7</td>
<td>Protease M</td>
</tr>
<tr>
<td>thioneins</td>
<td>Plectin</td>
<td>Filamin</td>
<td>Cystatin M</td>
</tr>
<tr>
<td></td>
<td>Filamin</td>
<td>K13</td>
<td>Amphotegin</td>
</tr>
<tr>
<td></td>
<td>Kallikrein 10</td>
<td>Protease M</td>
<td>Stronglyxin 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Collagenase 1</td>
</tr>
</tbody>
</table>

FIG. 6. Vitamin D-regulated genes in epithelial cancer cells. Genes that are positively or negatively regulated by 1,25-(OH)2D3 in prostate, colon, or breast cancer cells and keratinocytes/SCC are shown. The regulation of expression of these genes was confirmed by immunohistochemistry, Northern or Western blotting techniques.
glands is achieved by reduction of cyclin-dependent kinase (CDK) 2 activity as well as the induction of p21, p27, IGFBP-3, IGFBP-5, and E-cadherin expression (Fig. 6) (173, 178–180). The 1,25-(OH)₂D₃-mediated induction of p21 causes a decrease in CDK2 activity that leads to decreased phosphorylation of retinoblastoma protein and repression of E2F transcriptional activity resulting in growth arrest at the G₁ stage of the cell cycle. Induction of IGFBP-3 was found to be obligatory for 1,25-(OH)₂D₃-mediated growth inhibitory effect because IGFBP-3 antisense oligonucleotides or neutralizing antibodies abrogated the growth inhibition engendered by the VDR ligand in LNCaP cells. Furthermore, 1,25-(OH)₂D₃-mediated induction of p21 expression in LNCaP cells was also blocked by IGFBP-3 neutralizing antibodies, thus demonstrating that at least in LNCaP cells, p21 does not appear to be a direct target of vitamin D action (181).

Recently, a cDNA microarray analysis was performed on LNCaP, normal prostate, or prostatic adenocarcinoma of Gleason grade 3/3 treated with vehicle or 1,25-(OH)₂D₃ to identify VDR target genes and to elucidate the mechanism of action of 1,25-(OH)₂D₃ in prostate cancer cells (173). As expected, 24-hydroxylase was found to be maximally up-regulated by 1,25-(OH)₂D₃ in normal as well as primary cancer cells. However, in LNCaP cells, 24-hydroxylase expression was not induced by the VDR ligand. In LNCaP cells, the most vitamin D-responsive gene was found to be IGFBP-3, whereas primary cells did not show any up-regulation of IGFBP-3 expression. In both normal and cancer primary cells, the expression of the dual specificity phosphatase 10 was maximally induced by 1,25-(OH)₂D₃. Dual specificity phosphatase 10 inactivates MAPK, indicating that inhibition of the growth promoting actions of MAPK may at least in part explain the growth inhibitory actions of 1,25-(OH)₂D₃ in primary prostate cancer cells (173). The antioxidant effects of 1,25-(OH)₂D₃ in prostatic primary cultures were highlighted by the induced expression of thioredoxin reductase 1 and superoxide dismutase 2 (Fig. 6). Metallothioneins, most of the intracellular protein thiols that are thought to be antiapoptotic factors, show differential 1,25-(OH)₂D₃-dependent regulation in normal and primary prostate cancer cells. They show VDR ligand-mediated up-regulation in normal and down-regulation of expression in primary cancer cells, therefore indicating that 1,25-(OH)₂D₃ may induce antiapoptotic proteins in normal cells and apoptotic pathways in cancerous cells (173).

1,25-(OH)₂D₃ also induced the expression of 24-hydroxylase that catalyzes the first step of the 1,25-(OH)₂D₃ degradation pathway leading to calcitriol acid, which is excreted in bile. In prostate cancer cells, the extent of growth inhibition by 1,25-(OH)₂D₃ was found to be inversely proportional to 24-hydroxylase activity. DU145, a prostate cancer cell line that shows higher 1,25-(OH)₂D₃-induced expression of 24-hydroxylase, was less responsive to 1,25-(OH)₂D₃-mediated growth inhibition than LNCaP cells that showed very low basal and induced expression of 24-hydroxylase. Accordingly, liarozole, an inhibitor of P450 hydroxylases, elicited a significant 1,25-(OH)₂D₃-dependent growth inhibition in DU145 cells (182). Another cytochrome P450 hydroxylase inhibitor, ketoconazole, also augmented the growth inhibitory effects of 1,25-(OH)₂D₃ and its synthetic analog EB 1089 (Fig. 1) in primary human prostate cancer cells (183). Therefore, the use of 24-hydroxylase inhibitors may enhance the growth inhibitory activity of 1,25-(OH)₂D₃ and its synthetic analogs in prostate cancer. 1,25-(OH)₂D₃ has been shown to inhibit the proliferation of both androgen-dependent and androgen-independent prostate cancer cells. The growth inhibitory effects of 1,25-(OH)₂D₃ on LNCaP cells were androgen-dependent, because, casodex, an androgen receptor antagonist, blocked these effects. On the other hand, 1,25-(OH)₂D₃ inhibited the growth of androgen receptor-negative prostate cancer cells as well as cells derived from a patient with advanced androgen-independent prostate cancer (172, 184, 185).

Clinical trials with 1,25-(OH)₂D₃ in prostate cancer patients have highlighted the potential of VDR ligands either alone or in combination with other cytostatic agents. In a pilot study of seven patients with recurrent prostate cancer, oral calcitriol (0.5–2.5 μg/d) treatment for 6–15 months resulted in a significant decrease in the rate of prostate specific antigen (PSA) rise during therapy (in comparison to PSA increase before therapy) in six of seven patients (Table 1). In the seventh patient, the decrease in PSA rise did not reach statistical significance. As expected, the use of maximally intended calcitriol therapy was limited by the development of dose-dependent hypercalcemia (186). Generally, cancers are treated by a therapeutic regimen involving a combination of drugs. Therefore, differentiating molecules like 1,25-(OH)₂D₃ may sensitize tumor cells to cytotoxic effects of other chemotherapeutic agents. This premise was tested in a number of in vitro and in vivo studies, where 1,25-(OH)₂D₃ enhanced the antitumor effects of other chemotherapeutic agents, including cisplatin, paclitaxel, and adriamycin (187–189). These studies provided the basis for the use of combination therapy involving calcitriol and taxol in prostate cancer patients. In a clinical study, 37 patients with androgen-independent prostate cancer were treated with oral 1,25-(OH)₂D₃ (0.5 μg/kg) on d 1, followed by docetaxel (36 mg/m²) iv on d 2, and the regimen was repeated weekly for 6 consecutive weeks on an 8-wk cycle (Table 1). Patients were maintained on a reduced-calcium diet (400–500 mg calcium/d) and increased oral hydration. The primary end point was PSA response (50% decrease in PSA) that was confirmed in a second evaluation after 4 wk. Thirty of 37 patients achieved statistically significant PSA response, and 22 patients showed more than 75% reduction in PSA levels. This study demonstrated that the combination was better than the docetaxel treatment alone when PSA response rate, number of patients with more than 75% decrease in PSA, time to progression, or overall survival was compared with contemporary phase II clinical trials involving the administration of docetaxel as a single agent in androgen-independent prostate cancer patients (190). It is clear from these and other studies that prostate cancer treatment could benefit from additional development of noncalcemic vitamin D analogs.

BPH is the most common nonmalignant tumor in the aging male, and its pathogenesis also involves the regulation of prostate cell growth by androgen-dependent and androgen-independent growth factors (191). This process involves both prostate stromal and epithelial cells, because the messages for growth factors IGF-I and KGF (keratinocyte growth fac-
tor) were expressed in stromal cells, whereas their receptors were expressed in prostatic epithelial cells (192). VDR ligands inhibited the growth factor-stimulated proliferation of cells from human BPH (193, 194). Furthermore, a synthetic, less calcemic vitamin D analog (BXL-628/Ro-26-9228/RS-980400; Fig. 1) inhibited the androgen-induced ventral prostate weight in a dose-dependent manner in both intact and castrated rats. The effect of the VDR ligand was compared with that of antiandrogen, finasteride (194). Hypercalcemic properties of BXL-628/Ro-26-6228 are compared with calcitriol and presented in Table 3. Therefore, VDR ligands have potential as a new first-line therapy for the treatment of BPH.

VIII. Vitamin D Action on Breast Cancer Cells

Breast cancer strikes approximately 200,000 women in the United States each year, and nearly 40,000 succumb to the disease (195). Epidemiological studies have shown an inverse relationship between exposure to solar radiation and higher breast cancer incidence and mortality (196, 197). Another plausible link between 1,25-(OH)2D3 and breast cancer came to surface by the observation that chromosomal region 20q13.2, which contains 24-hydroxylase (CYP24), was amplified in breast cancer. Because 24-hydroxylase is involved in 1,25-(OH)2D degradation, its amplification may lead to decreased serum 1,25-(OH)2D levels, thus providing a microenvironment conducive for cell growth in the absence of vitamin D-mediated growth control (198). Furthermore, serum 1,25-(OH)2D levels were found to be reduced in advanced bone metastatic breast cancer patients more than in early stage patients (199). The VDR is expressed in most breast cancer cell lines, carcinogen-induced rat mammary tumors, normal breast tissues, as well as in primary breast cancer tumors. Furthermore, increased RXR and VDR protein levels were found in breast cancer tissues more than normal breast tissue (200, 201).

1,25-(OH)2D3 and its synthetic analogs have been shown to inhibit the proliferation of breast cancer cells in vitro and tumor progression in vivo (1, 200). One of the most interesting aspects of the action of VDR ligands is their efficacy in both ER-positive (MCF-7, T-47D, ZR-75-1, and SKBR-3) and ER-negative (BT-20, MDA-MB-435, MDA-MB-231, and SUM-159PT) breast cancer cells (1, 150, 202). Although the exact mechanism underlying the growth inhibitory actions of vitamin D in breast cancer cells is not clear, the data support a multipronged effect involving growth arrest at the G0/G1 stage, cell apoptosis, disruption of estrogen, and other growth factor-mediated cell survival signals and angiogenesis. The G0/G1 cell cycle arrest effects of VDR ligands on breast cancer cells could be explained by their ability to induce the expression of CDK inhibitors (CDKIs), p21CIP1/WAF1, and p27KIP1, in breast cancer and other epithelial cells (Fig. 6) (202–204). CDKIs inhibit the cell cycle progression by blocking the activity of cyclin-cyclin-dependent kinase (CDK) complexes, which are positive factors necessary for cell cycle progression. The identification of a VDRE in the CDK1 promoter indicated it to be an early mediator of vitamin D-mediated cell cycle arrest (28). Vitamin D-dependent induction of p27 is not mediated via a VDRE but depends on transcription factors specificity protein 1and NF-Y (205). In MCF-7 breast cancer cells, 1,25-(OH)2D3 also decreased the protein levels of CDK2, CDK4, cyclin D1, and cyclin A (Fig. 6) in a time-dependent manner (203, 206). 1,25-(OH)2D3 prevented the activation of cyclin D1-CDK4 and also resulted in the loss of cyclin D3, which leads to repression of E2F transcription factors and decreased cyclin A expression (204).

The antiproliferative effects of vitamin D on breast cancer cells could also be mediated by the induction of TGF-β1 and suppression of protooncogene c-myc (207, 208). 1,25-(OH)2D3 inhibited c-myc by inducing the expression of HOXB4, which binds to a specific DNA sequence in the c-myc promoter and blocks its transcriptional elongation (209). The natural VDR ligand also blocked the mitogenic activity of insulin and IGF-I on breast cancer cells, most probably by inducing the expression of IGFBP-3 and IGFBP-5 (Fig. 6) (210, 211). The molecular events involving cell cycle proteins lead to vitamin D-dependent induction of apoptosis, bax redistribution, decreased bcl-2 levels, cytochrome c release, polyADP ribose polymerase cleavage, external display of phosphatidylserine, and DNA fragmentation. Apart from having direct growth inhibitory effects, VDR ligands also inhibit angiogenesis and decrease the metastatic/invasive potential of breast cancer cell in vitro and in vivo (212–214). Similar to the rationale described for prostate cancer, treatment of breast cancer could be expanded to include combination therapies of VDR ligands with more common treatment regimes. As expected, 1,25-(OH)2D3 and its synthetic analogs augmented the cytotoxicity of doxorubicin, paclitaxel, adriamycin, and irradiation in breast cancer cell cultures (188, 215–217). An in vivo xenograft study has also demonstrated the interaction between a VDR ligand and paclitaxel or cisplatin treatment. In this model, additive antiproliferative effects were observed after combination treatment with the vitamin D3 analog CB 1093 (Fig. 1) with either paclitaxel or cisplatin (187). VDR ligands also have immense potential to act as chemopreventive agents because they blocked the progression of mammary carcinogenesis in vivo (218).

IX. Vitamin D Action on Colon Cancer Cells

Colon cancer, one of the most prevalent tumors in Western countries, is the second leading cause of cancer deaths in the United States. Epidemiological studies have suggested the involvement of vitamin D in the pathogenesis of colorectal tumors. An inverse association has been reported between calcium, vitamin D, milk intake, sunlight exposure, serum levels of 25-hydroxyvitamin D3, and colon cancer incidence/mortality (219, 220). Increased VDR protein was found in colonic tumors more than their normal counterparts (219). VDR+/− heterozygote and VDR−/− knockout animals showed increased proliferating cell nuclear antigen activity, cyclin D1 expression, and proliferation of cells in the colon descendens, thus indicating the importance of 1,25-(OH)2D3 in keeping a check on increased colonic proliferating activity (220). Apart from possessing VDR, colonic cells also possess the ability to synthesize 1,25-(OH)2D3 from its precursor...
25-hydroxyvitamin D₃ by the action of 1α-hydroxylase activity. All the above-mentioned observations indicate that VDR is potentially a very important therapeutic target for colorectal cancer prevention and treatment. 1,25-(OH)₂D₃ and its synthetic analogs inhibited the proliferation of colon cancer cells by affecting multiple pathways involving G₁ cell-cycle block, apoptosis, and cell differentiation (221–223). 1,25-(OH)₂D₃ induced differentiation of colon tumor cells and also potentiated butyrate/triutymin-induced differentiation of HT-29 colon cancer cells (224, 225). Interestingly, using a VDR antagonist, ZK 191732 (Fig. 1), it was discovered that butyrate-induced differentiation of Caco-2 cells was mediated by VDR (225).

In a study involving colon carcinoma cell lines (RG/C2, AA/C1, PC/JW, HT-29, and SW620), 1,25-(OH)₂D₃ and EB 1089 (Fig. 1) induced growth inhibition, differentiation marker (alkaline phosphatase), and apoptosis (226). Apoptosis occurred subsequent to differentiation, and it was consistently associated with increased levels of proapoptotic protein, Bak, in all the colon carcinoma cell lines tested. Decreased Bcl-2 was not observed in all five cell lines, and it was not associated with apoptosis. 1,25-(OH)₂D₃ and a synthetic analog, ZK 156718 (Fig. 1), also induced the expression of CDKIs p21 and p27 (Fig. 6) in Caco-2 cells (227). In SW480 cells, 1,25-(OH)₂D₃-induced differentiation was accompanied with an increase in E-cadherin and other adhesion proteins [occluding, zona occludens (ZO-1 and ZO-2), and vinculin] (Fig. 6). In these cells, 1,25-(OH)₂D₃ also promoted the translocation of β-catenin, plakoglobin, and ZO-1 from the nucleus to the plasma membrane. Furthermore, liganded VDR competed with T cell transcription factor (TCF)-4 for interaction with β-catenin, and as a result, 1,25-(OH)₂D₃ repressed β-catenin-TCF-4 transcriptional activity. VDR ligand also repressed the expression of β-catenin-TCF-4-responsive genes, c-myc, peroxisome proliferator activated receptor-δ, Tcf-1, and CD44, and it induced the expression of ZO-1 (223). Therefore, inhibition of β-catenin-TCF-4 signaling may be one of the molecular pathways involved in vitamin D₃ action in colon cancer cells. It was reported that the reduction of cyclin D1 levels was a key factor in the antiproliferative activity. All the above-mentioned observations indicate that VDR is potentially a very important therapeutic target for colorectal cancer prevention and treatment. 1,25-(OH)₂D₃ and its synthetic analogs inhibited the proliferation of colon cancer cells by affecting multiple pathways involving G₁ cell-cycle block, apoptosis, and cell differentiation (221–223).

XI. Vitamin D Action in Squamous Cell Carcinoma

The presence of VDR in keratinocytes and the ability of 1,25-(OH)₂D₃ to induce keratinocyte differentiation and in-
hibit their proliferation also indicated its potential usefulness in squamous cell carcinoma (SCC) of head and neck and aerodigestive tract. 1,25-(OH)2D3 inhibited the growth of SCC cells in vitro and in vivo (189, 244). However, unlike other tumor cells, 1,25-(OH)2D3 decreased the expression of p21 in a murine SCC model (189). Furthermore, overexpression of VDR target genes have been identified by expression profiling in EB 1089 (Fig. 1) treated head and neck SCC cells. The expression profile provided the molecular basis for the antiproliferative, differentiative, and genoprotective effects of VDR in SCC. The expression of 24-hydroxylase, protease M, cystatin M, amphiregulin, stromelysin, and collagenase I was induced, and that of CRABP-II, N-cadherin, and SCC antigen was inhibited by EB 1089 (Fig. 6) (247). A number of other genes involved in differentiation, cell growth inhibition, and immunomodulation pathways were identified, but their expression was not confirmed by other techniques.

II. Vitamin D Action in Kaposi's Sarcoma

KS is a highly vascular tumor that occurs predominantly in men with HIV infection. The herpes virus associated with KS also causes B cell lymphoma and primary effusion lymphoma. KS cell lines and primary KS and primary effusion lymphoma tumor tissue showed high levels of expression of VDR mRNA and protein, and their proliferation was inhibited by 1,25-(OH)2D3 in vitro and in vivo (248, 249). In an open clinical trial, topical treatment of KS lesions with calcipotriol showed antitumor activity in patients (249).

III. Vitamin D Action in Bone and Osteoporosis

Osteoporosis is a common metabolic disease characterized by reduced bone mass and microarchitectural deterioration of bone tissue that results in increased bone fragility and the risk of developing fractures. Various conditions that may lead to osteoporosis are estrogen deficiency, androgen deficiency, glucocorticoid excess, immobilization, hyperthyroidism, hyperparathyroidism, and space travel. Bone is one of the major target organs of vitamin D, and VDR ligands regulate both bone formation and resorption. Because of these actions, calcitriol and alfacalcidol (Fig. 1) have been used for the treatment of osteoporosis and osteomalacia, and several VDR ligands (ED-71, Ro-26-9228, and 2MD; Fig. 1) are under preclinical/clinical development for osteoporosis. VDR ligands may also exert their beneficial bone anabolic effects by enhancing intestinal calcium absorption and by inhibiting the synthesis of PTH. However, the mechanism of bone anabolic effects of 1,25-(OH)2D3 is not clear. 1,25-(OH)2D3 is classically considered to be a stimulator of bone resorption because it induces osteoclastogenesis by enhancing the expression of the RANKL in bone marrow stromal cells (250). Furthermore, human and mouse RANKL gene promoters contain a functional VDRE that shows RXR-VDR heterodimer-mediated ligand-dependent activation in the context of a reporter construct (23, 24). However, in vivo, VDR ligands decrease bone resorption and increase bone formation in ovariectomized animals and osteoporotic women. Therefore, 1,25-(OH)2D3 may show bone resorption in normal state and bone formation as well as antiresorption activities in osteoporotic state. Similar paradox is also observed in skin, where VDR ligands inhibit keratinocyte proliferation in psoriatic skin but induce epidermal proliferation in normal skin (251). Therefore, it appears that the differential action of 1,25-(OH)2D3 in normal and disease state is part and parcel of vitamin D pharmacology.

VDR is expressed at high levels in primary osteoblasts and various osteoblast cell lines, and they may hold the key to explaining the bone anabolic effects of 1,25-(OH)2D3 and its synthetic analogs (252). Osteoporosis involves the loss of both the organic and mineral contents of the bone. 1,25-(OH)2D3 increased the expression and/or protein levels of osteocalcin and osteopontin in osteoblasts, thus supporting its role in bone matrix formation (Fig. 2). A number of reports have shown prevention and decrease of vertebral fractures and an increase in total body and spine bone mineral density (BMD) in osteoporotic women with 1,25-(OH)2D3 treatment (6, 253–255). In a 3-yr study of 622 postmenopausal osteoporosis patients (Table 1) who had at least one vertebral compression fracture, calcitriol (0.25 Î¼g twice a day) was compared with treatment with supplemental elemental calcium (1 g/d). A significant reduction in vertebral fractures was observed during the second (9.3 vs. 25 fractures/100 patients) and third (9.9 vs. 31.5 fractures/100 patients) years of study in women taking calcitriol in comparison to calcium supplementation (255). In another clinical study involving postmenopausal women (n = 55), treatment with calcitriol (0.5 Î¼g/d) for 4 yr increased femoral neck BMD by 3%, whereas it was decreased by 1.9% in the control group (Table 1). Two years of treatment resulted in a 57% increase in intestinal strontium absorption (a measure of intestinal calcium absorption), a 100% increase in urinary calcium, and a 32% decrease in serum PTH levels. Of the 18 people treated with calcitriol, two developed hypercalcemia (6). However, the use of 1,25-(OH)2D3 as a treatment for osteoporosis is limited by its margin of safety, which appears to be very narrow, and there is a real risk of developing side effects (hypercalcemia and hypercalciuria) unless subjects are monitored closely, which, although possible in a clinical setting, is impractical in a real world treatment scenario. These unwanted effects result from an increase in calcium absorption through the intestine, leading to increased plasma and urine levels of calcium that can ultimately result in the mineralization of soft tissues and kidney stone formation.

Both prodrug and medicinal chemistry approaches have been explored in an effort to identify and synthesize less calcemic vitamin D3 analogs suitable for the treatment of osteoporosis. The prodrug approach resulted in the identification of alfacalcidol (1α-hydroxyvitamin D3), a precursor of 1,25-(OH)2D3 that gets enzymatically converted to the active hormone in liver by the action of 25-hydroxylase. As a result, its action on gut is somewhat reduced because enterocytes lack 25-hydroxylase, and therefore, alfacalcidol does not induce intestinal calcium absorption in the first pass when it is absorbed from the intestine. It has been found to reduce the incidence of vertebral fractures and increase bone
mass in several clinical trials (256). Success in treating osteoporosis with alfacalcidol is believed to be the result of the ability to administer higher doses of this compound compared with 1,25-(OH)2D3 before the detection of hypercalcemia (256, 257). It is currently an approved treatment for osteoporosis in Japan because the Japanese diet contains less calcium and therefore its side effect is manageable in that population.

Several attempts have been made to synthesize analogs of 1,25-(OH)2D3 that exhibit a lower occurrence of hypercalcemia in vivo. ED-71, a 25-dihydroxy-2β-(3-hydroxypropoxy) vitamin D4, (Fig. 1), is one example of such a compound (258).

In studies using normal, ovariectomized, and prednisolone-treated rats, ED-71 increased calcium absorption in the gut, decreased bone resorption, and increased bone mineralization (259, 260). ED-71 has also been found to be as effective as PTH in ovariectomized rats. At a dose of 0.08 μg/kg.d for 5 wk, ED-71 decreased bone resorption and increased bone mass without inducing hypercalcemia. In phase I studies in healthy human male volunteers (n = 40), ED-71 at oral doses of 0.1 to 1.0 μg for 15 d resulted in a dose-dependent increase in urinary calcium, but none of the subjects showed sustained hypercalciuria above 400 mg/d or hypercalcemia over 10.4 mg/dl. Based on these results, a phase II, open-label clinical trial with ED-71 (0.25, 0.5, 0.75, and 1.0 μg/d for 24 wk) was started with 109 osteoporosis patients. There was a dose-dependent increase in lumbar spine, and this effect was better than that obtained in historical studies with estrogen-treated patients. ED-71 was well tolerated in these patients, without causing any sustained hypercalcemia, and a dose of 0.75 μg/d was clinically effective (261).

Two secoстерoidal vitamin D analogs, Ro-26-9228 and 2MD (Fig. 1), are under preclinical development for osteoporosis. Ro-26-9228, a VDR modulator, was less potent than 1,25-(OH)2D3 in inducing the expression of 24-hydroxylase, calbindin D-9k, and plasma membrane calcium pump 1 in duodena of ovariectomized rats, whereas it was as potent as 1,25-(OH)2D3 in enhancing the expression of osteocalcin, osteopontin, and RANKL and decreased the expression of Cyp24 (24-hydroxylase), osteopontin, and RANKL and decreasing the expression of osteoprotegerin (265). 2MD was also more potent than 1,25-(OH)2D3 in inducing the interaction of VDR with RXR and cofactors SRC-1 and DRIP205.

However, there is still a safety issue with the current analogs because of their associated hypercalcemic activities. Optimal less calcemic vitamin D analogs have yet to be identified because most current 1,25-(OH)2D3 analogs have a small therapeutic window due to the development of hypercalcemia as a result of extended dosing.

XIV. Vitamin D Action on Blood Pressure

Hypertension is a major contributor to morbidity and mortality associated with heart attack, stroke, and end-stage renal disease. The renin-angiotensin system regulates blood pressure and salt/water homeostasis. Renin, a protease that is secreted by juxtaglomerular cells in nephrons, cleaves liver-derived angiotensinogen to angiotensin I. Angiotensin-converting enzyme then cleaves angiotensin I to angiotensin II, which modulates mammalian blood pressure by stimulating the synthesis of aldosterone by adrenal zona glomerulosa. Aldosterone stimulates sodium absorption and potassium secretion in the distal nephrons, and this process results in the expansion of blood volume leading to hypertension. Epidemiological studies have shown an inverse correlation between UV light exposure or plasma 1,25-(OH)2D3 levels and blood pressure. Furthermore, vitamin D supplementation and 1,25-(OH)2D3 treatment reduced blood pressure in hypertensive and hyperparathyroidism patients (218). VDR null mice also showed defects in the renin-angiotensin system. Renin expression in the kidney and plasma angiotensin II production were increased more in VDR knockout mice than in wild-type littermates, leading to hypertension, cardiac hypertrophy, and increased water intake (266).

Treatment of VDR null animals with captopril, an angiotensin-converting enzyme inhibitor, led to a decrease in blood pressure, thus confirming that the hypertension in VDR null animals was due to renin and angiotensin II elevation. Therefore, 1,25-(OH)2D3 appears to be a negative regulator of the renin-angiotensin system and may play a critical role in blood pressure homeostasis. Development of less calcemic VDR ligands could be useful therapeutically for the prevention and treatment of hypertension.

XV. Conclusions

In the past decade, numerous physiological, molecular, genetic, structural, and biochemical studies performed by basic and applied researchers have enhanced our understanding of the vitamin D signaling pathway and paved the way for the therapeutic exploitation of the VDR biology by medicinal chemists and drug discovery scientists. These studies have not only provided the nongut actions of vitamin D but also exposed various target indications responsive to VDR ligands. As a result, the therapeutic efficacy of VDR ligands in osteoporosis, psoriasis, and secondary hyperpara-
thyroidism has been well established. Based on a plethora of preclinical and clinical studies, arthritis, MS, type I diabetes, IBDs, myelodysplasia, leukemia, and cancers of prostate, colon, breast, and skin have emerged as additional vitamin D-responsive indications. The potential beneficial effects of VDR ligands in these indications were further corroborated by epidemiological studies. Despite this progress, the major hurdle still facing the translation of basic and applied research into therapeutic VDR ligands has been hypercalcemia/hypercalciuria. Although less calcemic analogs have been synthesized, they have not yet provided the desired separation between the therapeutic and calcemic action, and truly “noncalcemic” vitamin D analogs are still elusive. The calcemic liability of various vitamin D analogs is presented in Table 3. Therefore, a structure activity relationship-based medicinal chemistry effort for the identification and development of truly less calcemic ligands appears to be very important. Fortunately, increased understanding of the mechanism of vitamin D action has now provided the molecular and cellular tools necessary to identify tissue and gene-selective VDR modulators for various disease indications. Furthermore, the combination of VDR ligands, especially a new generation of VDR modulators with other differentiation inducers, histone deacetylase inhibitors, or chemotherapeutic regimens, may offer additive or synergistic activities in target diseases.

Acknowledgments

Address all correspondence and requests for reprints to: Sunil Nagpal, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285. E-mail: naggpal_sunil@lilly.com

References

8. Sutton AL, MacDonald PN 2003 Vitamin D: more than a “bone-a-fide” hormone. Mol Endocrinol 17:777–791
27. Freedman LP 1999 Transcriptional targets of the vitamin D receptor–mediating cell cycle arrest and differentiation. J Nutr 129:551


47. Masuyama H, MacDonald PN 1998 Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUGI interaction with the AF-2 domain of VDR. J Biol Chem 71:429–440


53. Lavigne AC, Mengus G, Gangloff YG, Wurtz JM, Davidson I 1999 Human TAF(I)55 interacts with the vitamin D(3) and thyroid hormone receptor as reators and with derivatives of the retinoid X receptor that have altered transactivation properties. Mol Cell Biol 19:5486–5494


60. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D 2000 The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 5:173–179


73. Chen CH, Sakai Y, Demay MB 2001 Targeting expression of the human vitamin D receptor to the keratinocytes of vitamin D receptor null mice prevents alopecia. Endocrinology 142:5386–5389


88. McGeer EF, DeLuca HF 2002 COL2 mutant cells are not necessary for 1,25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice. Proc Natl Acad Sci USA 99:5557–5560


684 Endocrine Reviews, August 2005, 26(5):662–687

Nagpal et al. • VDR


cyte growth factor and its receptor in human hyperplastic prostate tissue. J Clin Endocrinol Metab 83:2186–2191


235. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endoc Rev 20:345–357


241. Lau KH, Baylink DJ 1999 Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 65:295–306


Endocrine Reviews is published bimonthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.